Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $66.8 million.

  • Atara Biotherapeutics' Total Liabilities fell 7136.02% to $66.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.8 million, marking a year-over-year decrease of 7136.02%. This contributed to the annual value of $206.4 million for FY2024, which is 2204.24% down from last year.
  • Atara Biotherapeutics' Total Liabilities amounted to $66.8 million in Q3 2025, which was down 7136.02% from $71.9 million recorded in Q2 2025.
  • Atara Biotherapeutics' 5-year Total Liabilities high stood at $264.7 million for Q4 2023, and its period low was $66.8 million during Q3 2025.
  • For the 4-year period, Atara Biotherapeutics' Total Liabilities averaged around $196.7 million, with its median value being $228.2 million (2024).
  • In the last 5 years, Atara Biotherapeutics' Total Liabilities soared by 3709.38% in 2023 and then crashed by 7136.02% in 2025.
  • Atara Biotherapeutics' Total Liabilities (Quarter) stood at $249.8 million in 2022, then rose by 5.99% to $264.7 million in 2023, then fell by 22.04% to $206.4 million in 2024, then plummeted by 67.63% to $66.8 million in 2025.
  • Its Total Liabilities stands at $66.8 million for Q3 2025, versus $71.9 million for Q2 2025 and $117.1 million for Q1 2025.